TB-500 questions from around the workshop
These recurring questions span several experiments, and the answers have to leave room for unfinished human work.
What does TB-500 stand for?
“TB” refers to thymosin beta-4. TB-500 is the synthetic Ac-LKKTETQ fragment corresponding to positions 17–23 of that protein. The analytical paper establishes the fragment’s identity, while the thymosin beta-4 review concerns the much larger parent protein. TB in this name has no connection to tuberculosis.
When might an injury heal?
There is no validated human TB-500 healing timetable. In the rat wound experiment, full thymosin beta-4 increased new skin coverage by 42% at 4 days and up to 61% at 7 days. Those observations describe rat skin in that experiment. A human tendon injury, muscle tear or wound needs its own evidence before it can acquire a treatment timetable.
Can TB-500 help tendons or muscle tears?
The thymosin beta-4 review discusses preclinical tissue-repair and ligament work. The dystrophin-deficient mouse study found extra regenerating muscle fibers without significant improvement in strength. A controlled human test of tendon or muscle repair from the fragment remains missing. A human result linking tissue change to useful recovery would strengthen the claim considerably for me.
What about hair growth?
The parent-protein review discusses rodent hair-follicle work: full thymosin beta-4 stimulated follicle-related cell activity and hair growth. Controlled human hair-growth benefit from the TB-500 fragment has not been established. Online hair reports are anecdotal, and concurrent changes make individual accounts particularly difficult to interpret.
TB-500 and BPC-157
They are chemically different peptides with overlapping repair interests in preclinical research. TB-500 derives from thymosin beta-4; BPC-157 is a separate sequence associated with a protein from gastric fluid. The 2026 sports-medicine review discusses both in the context of unapproved peptide therapies and scarce human evidence.
Neither has FDA approval for human use. I regard a claimed clinical combination as unsupported by these sources. Neither peptide emerges as a proven repair treatment.
Human trials and FDA approval
The healthy-volunteer study tested full-length thymosin beta-4, and the clinical review also discusses topical and eye research on the parent protein. The short fragment has no completed controlled human trial establishing therapeutic benefit.
TB-500 has no FDA approval for human use. Its withdrawn nomination and absence from Category 2 on FDA’s page current as of April 22, 2026 do not confer that approval. The FDA and sport account gives the regulatory details, and reported effects covers the separate question of what people say they noticed.